BioCryst Pharmaceuticals Inc (BCRX) Debt by Year
BioCryst Pharmaceuticals Inc carried $0 in long-term debt against $89.7M in cash and equivalents at the end of fiscal year 2025. This represents a decrease of 100.0% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters BioCryst Pharmaceuticals Inc has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
BCRX Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $0-100.0% | $314.9M+3.8% | $303.2M+30.9% | $231.6M+70.2% | $136.1M+13.7% | $119.7M | N/A | $30.0M+30.4% | $23.0M0.0% | $23.0M | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $89.7M-14.3% | $104.7M-5.4% | $110.6M-63.7% | $304.8M-39.6% | $504.4M+85.4% | $272.1M+138.3% | $114.2M+327.1% | $26.7M-46.8% | $50.3M+127.5% | $22.1M-23.5% | $28.9M-47.0% | $54.5M+157.7% | $21.2M+1.3% | $20.9M+27.0% | $16.4M |
BCRX Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $395.4M+62.9% | $395.2M+25.3% | N/A | $194.4M-38.2% | $242.8M-22.6% | $315.4M+2.2% | $314.9M+3.8% | $314.3M+5.5% | $313.8M+7.0% | $308.5M+32.7% | $303.2M+30.9% | $298.0M+33.1% |
| Cash & Equivalents | $155.0M+76.0% | $171.6M+63.1% | $89.7M-14.3% | $84.1M-13.2% | $88.0M+12.3% | $105.2M+24.7% | $104.7M-5.4% | $96.8M-35.8% | $78.4M-46.4% | $84.3M-45.6% | $110.6M-63.7% | $150.9M-38.9% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More BioCryst Pharmaceuticals Inc financials
Frequently Asked Questions
What was BioCryst Pharmaceuticals Inc's long-term debt in fiscal year 2025?
BioCryst Pharmaceuticals Inc carried $0 in long-term debt against $89.7M in cash and equivalents at the end of fiscal year 2025.
How fast is BioCryst Pharmaceuticals Inc's long-term debt growing?
BioCryst Pharmaceuticals Inc (BCRX) long-term debt fell by 100.0% year over year, from $314.9M to $0 in fiscal year 2025.
What was BioCryst Pharmaceuticals Inc's long-term debt in the most recent quarter?
BioCryst Pharmaceuticals Inc (BCRX) reported $395.4M in long-term debt in Q2 2026. This represents an increase of 62.9% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what BioCryst Pharmaceuticals Inc (BCRX) reported on that line in every period on record.